MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.

by Horiuchi, Dai, Kusdra, Leonard, Huskey, Noelle E, Chandriani, Sanjay, Lenburg, Marc E, Gonzalez-Angulo, Ana Maria, Creasman, Katelyn J, Bazarov, Alexey V, Smyth, James W, Davis, Sarah E, Yaswen, Paul, Mills, Gordon B, Esserman, Laura J, Goga, Andrei
Published 2012

PIM1 kinase is essential for the growth of MYC-overexpressing triple-negative breast tumors and is an efficacious therapeutic target

by Horiuchi, Dai, Zhou, Alicia Y, Corella, Alexandra N, Yau, Christina, Lawson, Devon A, Bazarov, Alexey V, Yaswen, Paul, McManus, Michael T, Welm, Alana L, Werb, Zena, Goga, Andrei
Published 2013